Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

• ClinicalTrials.gov Identifier: NCT00648011
• Recruitment Status: Completed
• First Posted: April 1, 2008
• Last Update Posted: April 1, 2008
• Sponsor: Mylan Pharmaceuticals Inc
• Information provided by: MylanPharma

Study Description

Brief Summary:

The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20mg/ 25 mg tablets following a single, oral 20/25 mg (1 x 20/25 mg) dose administration under fed conditions.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg; Drug: Accuretic™ Tablets 20 mg/25 mg	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 44 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Official Title: Single-Dose Food In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers
• Study Start Date: August 2003
• Actual Primary Completion Date: August 2003
• Actual Study Completion Date: September 2003

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg	Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg; 20/25mg, single dose fed
Active Comparator: 2; Accuretic™ Tablets 20 mg/25 mg	Drug: Accuretic™ Tablets 20 mg/25 mg; 20/25mg, single dose fed

Outcome Measures

Primary Outcome Measures :

1. Bioequivalence [ Time Frame: within 30 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Age: 18 years and older.

2. Sex: Male and/or non-pregnant, non-lactating female.

   1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on weekends, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (beta-HCG) pregnancy test will be performed upon completion of the study.

   2. Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. Acceptable forms of contraception include the following:

      1. intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
      2. barrier methods containing or used in conjunction with a spermicidal agent, or
      3. surgical sterility (tubal ligation, oophorectomy or hysterectomy) or postmenopausal accompanied with a documented postmenopausal course of at least one year
   3. During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form.
3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and all subjects within 15% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
4. All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, hepatitis B and hepatitis C tests, HIV test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.

Exclusion Criteria:

1. Institutionalized subjects will not be used.

2. Social Habits:

   1. Use of any tobacco products within 1 year of the start of the study.
   2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
   3. Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.
   4. Any recent, significant change in dietary or exercise habits.
   5. A positive test for any drug included in the urine drug screen.
   6. History of drug and/or alcohol abuse.

3. Medications:

   1. Use of any prescription or over-the-counter (OTC) medications within the 14 days prior to the initial dose of study medication.
   2. Use of any hormonal contraceptives and hormonal replacement therapy within 3 months of the start of the study.
   3. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.

4. Diseases:

   1. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic disease.
   2. Acute illness at the time of either the pre-study medical evaluation or dosing.
   3. A positive HIV, hepatitis B or Hepatitis C test.

5. Abnormal and clinically significant laboratory test results:

   1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
   2. Abnormal and clinically relevant ECG tracing.
6. Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
8. Allergy or hypersensitivity to quinapril, hydrochlorothiazide, or other related products
9. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.

Contacts and Locations

Locations

United States, North Dakota

PRACS Institute, Ltd.

Fargo, North Dakota, United States, 58104

Sponsors and Collaborators

Mylan Pharmaceuticals Inc

Investigators

• Principal Investigator: James D Carlson, Pharm. D.; PRACS Institute Ltd.

More Information

Additional Information:

Mylan Pharmaceuticals Inc. - Clinical Trial Results 

Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use 

Recalls, Market Withdrawals and Safety Alerts 

• Responsible Party: Will Sullvan, Global Head of Product Risk and Safety Management, Mylan Inc.
• ClinicalTrials.gov Identifier: NCT00648011
• Other Study ID Numbers: QUTZ-0312
• First Posted: April 1, 2008
• Last Update Posted: April 1, 2008
• Last Verified: March 2008

Additional relevant MeSH terms:

Hydrochlorothiazide; Quinapril; Antihypertensive Agents; Diuretics; Natriuretic Agents; Physiological Effects of Drugs; Sodium Chloride Symporter Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Angiotensin-Converting Enzyme Inhibitors; Protease Inhibitors; Enzyme Inhibitors